Elidel (Pimecrolimus)
pimecrolimus 1% cream, 15 g · APPLICATION · PBS code 8802G
STREAMLINEDWhat it costs
AU$19.13 PBS-determined price per 1 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2005-04-01.
- • Repeats: 1.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Atopic dermatitis
Patient must be at least 3 months of age; AND
The condition must be on the patient's face; or
The condition must be on the patient's eyelid; AND
Patient must have 1 or more of the following contraindications to topical corticosteroids: (i) perioral dermatitis; (ii) periorbital dermatitis; (iii) rosacea; (iv) epidermal atrophy; (v) dermal atrophy; (vi) allergy to topical corticosteroids; (vii) cataracts; (viii) glaucoma; (ix) raised intraocular pressure; AND
Patient must not receive more than two 15 g packs of PBS-subsidised pimecrolimus per 6-month period.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Atopic dermatitis
Short-term (up to 3 weeks) intermittent treatment
Patient must be at least 3 months of age; AND
The condition must be on the patient's face; or
The condition must be on the patient's eyelid; AND
Patient must have failed to achieve satisfactory disease control with intermittent topical corticosteroid therapy; AND
The condition must have been initially diagnosed more than three months prior to this treatment; AND
Patient must not receive more than two 15 g packs of PBS-subsidised pimecrolimus per 6-month period.
Failure to achieve satisfactory disease control with intermittent topical corticosteroid therapy is manifest by:
(i) failure of the facial skin to clear despite at least 2 weeks of topical hydrocortisone 1% applied every day; or
(ii) failure of the facial skin to clear despite at least 1 week of a moderate or potent topical corticosteroid applied every day; or
(iii) clearing of the facial skin with at least 2 weeks of topical hydrocortisone 1% applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions; or
(iv) clearing of the facial skin with at least 1 week of a moderate or potent topical corticosteroid applied every day, but almost immediate and significant flare in facial disease (within 48 hours) upon stopping topical corticosteroids, occurring on at least 2 consecutive occasions
Sponsor: Viatris Pty Ltd ABN 29 601 608 771
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.